AstraZeneca's tralokinumab trial in IPF gets helping hand from Brainomix's AI tool

2024-03-27

临床2期

Brainomix's AI-powered automated CT processing software successfully helped identify idiopathic pulmonary fibrosis (IPF) patients at risk of decline in a clinical trial of AstraZeneca's IL-13 monoclonal antibody tralokinumab. The drug is already sold as Adtralza/Adbry for atopic dermatitis.

According to the findings recently published in the American Journal of Respiratory and Critical Care Medicine, Brainomix's e-Lung software outperforms standard methods in stratifying patients at risk of IPF progression. The University of Oxford spinout believes the results underscore the tool's potential to improve the efficiency of future clinical trials.

Patient data from AstraZeneca's Phase II trial of tralokinumab was processed with Brainomix's software. The tool has been trained using thousands of CT scans and is powered by the weighted reticulovascular score (WRVS). This novel biomarker incorporates reticular opacities and vascular structures of the lung.

Optimising clinical trials

Brainomix's senior medical director Peter George, who led the study, said his team has shown that "from a single baseline CT scan, WRVS is able to identify patients at risk of decline in Forced Vital Capacity (FCV) over the next 52 weeks." He noted that the data suggest that the tool may "allow for enrichment of clinical trials with progressive patients, could identify patients at low risk of IPF progression, might facilitate well-matched treatment arms and could reduce the size of future clinical trials."

Results presented at last year's American Thoracic Society meeting showed that WRVS was more strongly associated with transplant free survival of IPF patients than FVC alone. WRVS was also able to predict both short- and long-term outcomes of the patients, including lung function decline and survival.

Brainomix has collaborated with several notable partners, including Boehringer Ingelheim, Bridge Biotherapeutics, Stryker, Argenica and Lumosa.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

适应症

靶点

药物